Search

Your search keyword '"Snook AE"' showing total 98 results

Search Constraints

Start Over You searched for: Author "Snook AE" Remove constraint Author: "Snook AE"
98 results on '"Snook AE"'

Search Results

1. CD8α Structural Domains Enhance GUCY2C CAR-T Cell Efficacy.

2. CD5 deletion enhances the antitumor activity of adoptive T cell therapies.

3. GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults.

4. Biomarkers for Managing Neurodegenerative Diseases.

5. In vitro assays to evaluate CAR-T cell cytotoxicity.

6. Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15.

7. GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults.

8. IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism.

9. Intestinal neuropod cell GUCY2C regulates visceral pain.

10. Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy.

11. The poorly immunogenic tumor microenvironment of pancreatic cancer: the impact of radiation therapy, and strategies targeting resistance.

12. Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.

13. Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer.

14. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.

15. Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy.

16. Functional Assessment of Missense Variants in the ABCC6 Gene Implicated in Pseudoxanthoma Elasticum, a Heritable Ectopic Mineralization Disorder.

17. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.

18. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.

19. Emerging drug targets for colon cancer: A preclinical assessment.

20. Genetic heterogeneity of heritable ectopic mineralization disorders in a large international cohort.

21. Evaluation of CAR-T cell cytotoxicity: Real-time impedance-based analysis.

22. A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.

23. Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment.

24. The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission.

25. From leptin to lasers: the past and present of mouse models of obesity.

26. Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers.

27. Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers.

28. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.

29. Stem cells as therapeutic targets in colorectal cancer.

30. Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.

31. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

32. Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity.

33. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.

34. Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies.

35. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.

36. pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity.

37. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.

38. Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin.

39. Non-Thermal Plasma-Induced Immunogenic Cell Death in Cancer: A Topical Review.

40. Biomarker targeting of colorectal cancer stem cells.

41. Adenovirus-Mediated ABCC6 Gene Therapy for Heritable Ectopic Mineralization Disorders.

42. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.

43. Therapeutic targeting of gastrointestinal cancer stem cells.

44. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.

45. TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.

46. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.

47. Non-thermal plasma induces immunogenic cell death in vivo in murine CT26 colorectal tumors.

48. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress.

49. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.

50. Immunotherapy regimens for metastatic colorectal carcinomas.

Catalog

Books, media, physical & digital resources